Aventis buys Caliper 250 system

June 25, 2003 — Caliper Technologies Corp. announced that Aventis Pharmaceuticals Inc. bought the Caliper 250 drug discovery system, according to a news release.

Aventis intends to develop a series of screening tests using Caliper’s LabChip applications with the potential to make customized assays and chips. The tests are for screening of kinase, an enzyme that catalyzes actions in proteins.

Caliper, which trades on Nasdaq, closed Tuesday at 4.40, up from 4.30 on Monday.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.